Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Guideline
. 2021 Apr 1;21(2):120-135.
doi: 10.17305/bjbms.2020.4846.

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Semir Bešlija  1 , Zdenka Gojković  2 , Timur Cerić  1 , Alma Mekić Abazović  3 , Inga Marijanović  4 , Semir Vranić  5 , Jasminka Mustedanagić-Mujanović  6 , Faruk Skenderi  1 , Ivanka Rakita  2 , Aleksandar Guzijan  2 , Dijana Koprić  6 , Alen Humačkić  7 , Danijela Trokić  8 , Jasmina Alidžanović  6 , Alma Efendić  3 , Ibrahim Šišić  3 , Harun Drljević  3 , Vanesa Bešlagić  1 , Božana Babić  2 , Azra Pašić  3 , Anela Ramić  3 , Dijana Mikić  2 , Zlatko Guzin  7 , Dragana Karan  4 , Teo Buhovac  4 , Dragana Miletić  4 , Senad Šečić  1 , Azra Đozić Šahmić  1 , Lejla Mujbegović  3 , Alisa Kubura  3 , Mensura Burina  6 , Nenad Lalović  9 , Nikolina Dukić  9 , Jelena Vladičić Mašić  9 , Mirjana Ćuk  9 , Rajna Stanušić  9
Affiliations
Guideline

2020 consensus guideline for optimal approach to the diagnosis and treatment of HER2-positive breast cancer in Bosnia and Herzegovina

Semir Bešlija et al. Bosn J Basic Med Sci. .

Abstract

The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declare no conflict of interests

Figures

FIGURE 1
FIGURE 1
Number of newly diagnosed cancers among women in Bosnia and Herzegovina in 2018 (GLOBOCAN 2018) [1].
FIGURE 2
FIGURE 2
Algorithm for the assessment of human epidermal growth factor (HER2) protein expression by IHC analysis of invasive component of breast cancer sample [10].
FIGURE 3
FIGURE 3
Algorithm for the evaluation of human epidermal growth factor receptor (HER2) gene amplification using the in situ hybridization (ISH) method of an invasive component of a breast cancer sample using a double signal test (HER2 gene) [7].
FIGURE 4
FIGURE 4
Surgical staging and axillary dissection algorithm.
FIGURE 5
FIGURE 5
Algorithm of adjuvant anti-HER2 therapy after neoadjuvant treatment, taking into consideration pathologic complete response as a decision point for further therapy [17].
See this image and copyright information in PMC

References

    1. Ferlay J, Soerjomataram I. [Last accessed on 2019 Sep 16]. Available from: http://www.globocan.iarc.fr .
    1. Institut zајаvnоzdrаvstvоRеpublikеSrpskе. [Last accessed on 2019 Sep 16]. Available from: https://www.phi.rs.ba .
    1. Wilson AR, Marotti L, Bianchi S, Biganzoli L, Claassen S, Decker T, et al. The requirements of a specialist breast centre. Eur J Cancer. 2013;49:3579–87. - PubMed
    1. Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E, et al. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2015;25(12):3669–78. - PMC - PubMed
    1. Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, et al. Early breast cancer:ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30:1194–220. https://doi.org/10.1093/annonc/mdz173. - PubMed

Publication types